sar425899 glucagon glp-1 dual agonist sanofi Role of a Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor (Twincretin) in Glycemic Control: From Pathophysiology to Treatment Frontiers | Striking the Balance:

This comprehensive review critically evaluates recent advances in BBRs anti-obesity pharmacology through three lenses: (1) preclinical and clinical evidence from randomized controlled trials, (2) molecular mechanisms underlying metabolic regulation, and (3) innovative strategies for pharmacokinetic optimization

GLP-1RA medications are the first pharmacotherapy for obesity with demonstrable cardiovascular benefits and ASCVD risk reduction

The mechanisms underlying these effects involve the modulation of signaling pathways associated with cell growth, survival, and metabolism

Probiotics promote gut and digestive health, which play a role in overall wellness.*

Given the potential for increased INR variability, clinicians may consider increasing INR monitoring frequency following GLP-1 RA initiation.

Our blog series on GLP-1 agonists for weight loss is aimed at unpacking the science behind this new frontier in weight management, presenting a detailed overview of how they work, their efficacy, and their role in a holistic approach to health and wellness.